Apellis Pharmaceuticals' Upcoming Presence at Investor Events

Author: Evelyn Baker Updated: 08-27-2025 07:18 AM

Apellis Pharmaceuticals: Engaging Investors Through Conferences

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is set to engage with investors through a series of prominent conferences. This marks a significant opportunity for the company to showcase its progress and innovations in biopharmaceuticals, particularly in the realm of complement science. With the aim of addressing some of the toughest diseases in the healthcare space, Apellis is steadily carving out its reputation as a trailblazer in developing life-changing therapies.

Overview of Upcoming Conferences

Apellis will participate in the following conferences, where management will be involved in informative webcast fireside chats:

Wells Fargo Healthcare Conference

Scheduled for Wednesday, September 3, 2025, at 8:45 a.m. ET, the Wells Fargo Healthcare Conference presents a platform for Apellis to discuss its vision and strategic initiatives.

Cantor Global Healthcare Conference

The following day, Thursday, September 4, 2025, at 8:35 a.m. ET, Apellis will participate in the Cantor Global Healthcare Conference, further illustrating its commitment to transparency and investor communication.

Baird Global Healthcare Conference

On September 9, 2025, at 10:15 a.m. ET, Apellis will appear at the Baird Global Healthcare Conference, providing additional insights into its growth strategy and future planning.

Live Webcasts and Replays

These live conference webcasts will be accessible via the "Events and Presentations" page located in the "Investors and Media" section of the company's website. After the events, a replay of each webcast will be available for at least 30 days, allowing broader access to Apellis's insights and updates for those who cannot attend live.

About Apellis Pharmaceuticals

Established as a leading biopharmaceutical company, Apellis Pharmaceuticals focuses on leveraging complement science to deliver transformative therapies for patients suffering from challenging diseases. The company's pioneering efforts have led to the introduction of the first new class of complement medicine in over 15 years. Currently, Apellis boasts two approved C3-targeting medicines that aim to address significant health challenges, including the first-ever therapy for geographic atrophy—a condition that can lead to blindness—and an innovative treatment for severe kidney diseases affecting patients aged 12 and older.

The Future of Complement Medicine

As Apellis looks to the future, it remains optimistic about the untapped potential within the field of C3-targeting therapies. The company is committed to expanding its research and development efforts, with an eye towards identifying new applications that could help even more patients in need of effective treatments.

Investor Contact Information

For further inquiries or additional information, interested parties can reach out to Eva Stroynowski at Apellis Pharmaceuticals:

Email: eva.stroynowski@apellis.com

Phone: 617.938.6229

Frequently Asked Questions

What is Apellis Pharmaceuticals known for?

Apellis Pharmaceuticals is recognized for developing innovative therapies focused on complement science, targeting diseases that are challenging to treat.

When will Apellis participate in the upcoming conferences?

The company will participate in a series of conferences on September 3, 4, and 9, 2025.

How can I access the live webcasts?

Live webcasts can be accessed via the "Events and Presentations" page on Apellis's official website.

Are there any therapies approved by Apellis?

Yes, Apellis has two approved C3-targeting therapies aimed at treating various serious conditions.

Who can I contact for investor relations?

For inquiries related to investor relations, you can contact Eva Stroynowski via email or phone as provided above.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.